ALACRiS Theranostics GmbH, founded in 2008 in Berlin, is a pioneer of precision medicine. With innovative solutions in genomics and oncology, the company offers high-quality diagnostics and NGS services to best support cancer patients.
ALACRiS Theranostics GmbH, founded in 2008 in Berlin, is a pioneer in the fields of technology development, genomics, next-generation sequencing, and systems biology. The company was established by pioneers in these fields with the goal of translating research results into direct benefits for patients and society.
The mission of ALACRiS Theranostics is to develop innovative concepts and sustainable solutions for revolutionizing healthcare, discovering biomarkers, and drug development. A particular focus is on molecular oncology and precision medicine. The company strives to make the benefits of precision medicine accessible to every cancer patient and offers best-in-class accredited diagnostic services that combine state-of-the-art next-generation sequencing (NGS) with a proprietary bioinformatics pipeline[3][4].
ALACRiS Theranostics is committed to developing sustainable solutions for healthcare while adhering to the highest quality and safety standards. The company is ISO 15189 accredited and meets strict quality management and data protection standards, including GDPR regulations. Through partnerships with academic institutions, biotechnology, and pharmaceutical companies, ALACRiS promotes the advancement of research and the implementation of innovative solutions in clinical practice[1][3].
ALACRiS Theranostics recently received IVD-CE certification for a highly precise PCR test for the detection of SARS-CoV-2 viruses, underscoring the company's ability to respond quickly and effectively to health challenges[2].
Through its innovative approach and commitment to precision medicine, ALACRiS Theranostics positions itself as a leading company in cancer diagnostics and therapy, aiming to shape the future of medical diagnostics and treatment.
